Skip to content
Palladio Biosciences

Palladio Biosciences

Working to bring new hope to patients with orphan diseases of the kidney
  • Home
  • Polycystic Kidney Disease
  • Pipeline
  • Clinical Trials
  • Information Resources
  • About Us
  • News
  • Contact

Palladio Biosciences Announces First Patient Dosed With Lixivaptan in The ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued From Treatment With Tolvaptan Due to Liver Toxicity

November 17, 2020 Vera

HORSHAM, Pa.–(BUSINESS WIRE)– Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 Meeting

October 20, 2020 Vera

HORSHAM, Pa.–(BUSINESS WIRE)–Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney,…

Continue Reading →

Posted in: Press Release

PALLADIO COMPLETES $20 MILLION SERIES B FINANCING

September 25, 2020 Vera

Financing round led by Samsara BioCapital to advance Phase 3 ALERT Study.  HORSHAM, Pa. – September 25, 2020 Palladio Biosciences,…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Announces Presentations of ELiSA Phase 2 Study Results and Phase 3 Lixivaptan Clinical Program Design during the American Society of Nephrology Kidney Week 2019 Meeting

November 5, 2019 Palladio Biosciences

NEWTOWN, Pa. — Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Appoints Marella Thorell Chief Financial Officer

October 11, 2019 Palladio Biosciences

NEWTOWN, Pa.–(BUSINESS WIRE)–Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/, a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney,…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Appoints Alex Martin Chief Executive Officer

August 8, 2019 Palladio Biosciences

NEWTOWN, Pa. — Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Announces Appointment of Sanford (Sandy) Zweifach as Chairman of its Board of Directors

April 3, 2019 Palladio Biosciences

–Addition of Experienced Executive to Leadership Team– Newtown, PA:  April 3, 2019.  Palladio Biosciences, Inc. (Palladio) https://palladiobio.com/, a private biopharmaceutical…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Appoints Neil H. Shusterman, M.D., as Chief Medical Officer

January 3, 2019 Palladio Biosciences

–Dr. Shusterman named as Palladio Biosciences, Inc., Chief Medical Officer– January 03, 2019 09:20 AM Eastern Standard Time NEWTOWN, Pa.–(BUSINESS…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

December 18, 2018 Palladio Biosciences

–ELiSA Study designed to evaluate the safety and activity of multiple doses of lixivaptan in patients with ADPKD– December 18,…

Continue Reading →

Posted in: Press Release

Palladio Biosciences Receives FDA IND Clearance to Begin the ELiSA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

May 8, 2018 Palladio Biosciences

–Patient enrollment into the study expected to begin by the end of June 2018– NEWTOWN, Pa., May 8, 2018 –(BUSINESS…

Continue Reading →

Posted in: Press Release

Post navigation

Page 1 of 2
1 2 Next →

Archives

  • Press Release
  • Publications

Please note that lixivaptan is for investigational use only.

Palladio Biosciences
5 Walnut Grove Drive
Suite 120
Horsham, PA 19044
info@palladiobio.com

Copyright © Palladio Biosciences.